# Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

> **NCT03821077** · — · COMPLETED · sponsor: **Roxall Medicina España S.A** · enrollment: 122 (actual)

## Conditions studied

- Rhinitis, Allergic
- Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** Allergen Immunotherapy (AIT)

## Key facts

- **NCT ID:** NCT03821077
- **Lead sponsor:** Roxall Medicina España S.A
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-30
- **Primary completion:** 2021-09-13
- **Final completion:** 2021-09-13
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821077, "Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03821077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*